Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Elliot S, Barnathan"'
Autor:
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M. Bauersachs, Scott D. Berkowitz, Lloyd Haskell, Elliot S. Barnathan, Marc P. Bonaca
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 8 (2024)
Background The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Externí odkaz:
https://doaj.org/article/cb7732979fc142828382971a3178e404
Autor:
Alex C. Spyropoulos, Gary E. Raskob, Theodore E. Spiro, Wentao Lu, Yoriko De Sanctis, John Albanese, Alexandre Mebazaa, Elliot S. Barnathan
Publikováno v:
TH Open, Vol 06, Iss 04, Pp e304-e308 (2022)
This post hoc subgroup analysis examined efficacy and safety outcomes with extended thromboprophylaxis rivaroxaban compared with in-hospital enoxaparin in 2,078 patients from the MAGELLAN study who had a hospitalization for heart failure or a history
Externí odkaz:
https://doaj.org/article/c30a282dfc12451e8dc11369d84e91b0
Autor:
Gary E. Raskob, Walter Ageno, Gregory Albers, C. Gregory Elliott, Jonathan Halperin, Gregory Maynard, Philippe Gabriel Steg, Jeffrey I. Weitz, John Albanese, Zhong Yuan, Bennett Levitan, Wentao Lu, Eun Young Suh, Theodore Spiro, Concetta Lipardi, Elliot S. Barnathan, Alex C. Spyropoulos
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 20 (2022)
Background Venous thromboembolism (VTE) often occurs after hospitalization in medically ill patients, but the population benefit–risk of extended thromboprophylaxis remains uncertain. Methods and Results The MARINER (Medically Ill Patient Assessmen
Externí odkaz:
https://doaj.org/article/3f35590df43c41208e8ddc289edabcaa
Autor:
Alex C. Spyropoulos, Mark Goldin, Walter Ageno, Gregory W. Albers, C. Gregory Elliott, William R. Hiatt, Jonathan L. Halperin, Gregory Maynard, P. Gabriel Steg, Jeffrey I. Weitz, Theodore E. Spiro, Wentao Lu, Jessica Marsigliano, Gary E. Raskob, Elliot S. Barnathan
Publikováno v:
TH Open, Vol 06, Iss 03, Pp e177-e183 (2022)
Background The MARINER trial evaluated whether postdischarge thromboprophylaxis with rivaroxaban could reduce the primary outcome of symptomatic venous thromboembolism (VTE) or VTE-related death in acutely ill medical patients at risk for VTE. Althou
Externí odkaz:
https://doaj.org/article/8d224873bb1841ca8d9854b241be5ec7
Autor:
Gary E. Raskob, Alex C. Spyropoulos, Theodore E. Spiro, Wentao Lu, Zhong Yuan, Bennett Levitan, Eunyoung Suh, Elliot S. Barnathan
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 22 (2021)
Background Thromboprophylaxis extended after hospital discharge in medically ill patients currently is not recommended by practice guidelines because of uncertainty about the benefit for preventing major or fatal thromboembolic events, and the risk o
Externí odkaz:
https://doaj.org/article/b3ae24eeae734c9d9ca797881cf8076b
Autor:
Concetta Lipardi MD, PhD, C. Gregory Elliott MD, Chiara L. Sugarmann BSN, MSHS, Lloyd Haskell MD, Alex C. Spyropoulos MD, Gary E. Raskob PhD, Jianfeng Xu PhD, Wentao Lu PhD, Jessica Marsigliano BS, Theodore Spiro MD, Zhong Yuan MD, PhD, Shujian Wu MD, PhD, Elliot S. Barnathan MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
Background: Bronchiectasis is a chronic inflammation of the bronchi with recurrent infections and hemoptysis. The MAGELLAN study compared oral rivaroxaban, 10 mg once daily (QD), for 35 ± 4 days with subcutaneous enoxaparin 40 mg QD for 10 ± 4 days
Externí odkaz:
https://doaj.org/article/1fd0b5a345ce4677b3379b0cff1e47c1
Publikováno v:
American Journal of Cardiovascular Drugs. 23:247-255
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1e494287877b1de6c130929c6cfe9b6
https://doi.org/10.1007/s40256-023-00579-4
https://doi.org/10.1007/s40256-023-00579-4
Autor:
Gary E. Raskob, Alex C. Spyropoulos, Alexander T. Cohen, Jeffrey I. Weitz, Walter Ageno, Yoriko De Sanctis, Wentao Lu, Jianfeng Xu, John Albanese, Chiara Sugarmann, Traci Weber, Concetta Lipardi, Theodore E. Spiro, Elliot S. Barnathan
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 5 (2021)
Background Asymptomatic proximal deep vein thrombosis (DVT) is an end point frequently used to evaluate the efficacy of anticoagulant thromboprophylaxis in medical patients. Recently, the clinical relevance of asymptomatic DVT has been challenged. Me
Externí odkaz:
https://doaj.org/article/76037fab5c754e27b468a9743e724d78
Autor:
Colin Pawlowski, Tyler Wagner, Arjun Puranik, Karthik Murugadoss, Liam Loscalzo, AJ Venkatakrishnan, Rajiv K Pruthi, Damon E Houghton, John C O'Horo, William G Morice II, Amy W Williams, Gregory J Gores, John Halamka, Andrew D Badley, Elliot S Barnathan, Hideo Makimura, Najat Khan, Venky Soundararajan
Publikováno v:
eLife, Vol 9 (2020)
Temporal inference from laboratory testing results and triangulation with clinical outcomes extracted from unstructured electronic health record (EHR) provider notes is integral to advancing precision medicine. Here, we studied 246 SARS-CoV-2 PCR-pos
Externí odkaz:
https://doaj.org/article/9f6ab82066544f2bb214b876c4098a59
Autor:
Alex C. Spyropoulos, Concetta Lipardi, Jianfeng Xu, Colleen Peluso, Theodore E. Spiro, Yoriko De Sanctis, Elliot S. Barnathan, Gary E. Raskob
Publikováno v:
TH Open, Vol 04, Iss 01, Pp e59-e65 (2020)
An individualized approach to identify acutely ill medical patients at increased risk of venous thromboembolism (VTE) and a low risk of bleeding to optimize the benefit and risk of extended thromboprophylaxis (ET) is needed. The International Medical
Externí odkaz:
https://doaj.org/article/3770033c4d1b43058b978ef08e426bb1